| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.7 | 1.4 |
| Net income | -8.7 | -4.4 |
| EPS (diluted, $ a share) | $-1.14 | $-1.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -48.3% |
|---|
10-Q filed with the SEC, NASDAQ: CNSY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cerenome, Inc.: key numbers
- Share price
- $0.7148Close, Nov 16
- Market cap
- $6.99M
- Shares outstanding
- 9.78MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cerenome, Inc.
All →Cerenome Earnings Call: Key Takeaways
Cerenome is transitioning to a commercial-stage entity with CNSide diagnostic revenue scaling and Rheobic radiopharmaceutical trials meeting key safety and enrollment milestones for 2027 readouts.
- Call
- Nov 16, 2026, 8:30 AM ET
Cerenome Clinical Trial Data
Cerenome reported interim data from its Phase 1 ReSPECT-LM study evaluating repeat dosing of REYOBIQ in patients with leptomeningeal metastases. The data showed no dose-limiting toxicities in the first 10 patients and indicated consistent radiation delivery across repeat administrations, with early disease control signals showing no progression in evaluable patients at the six-month landmark.
- Counterparty
- Society for Neuro-Oncology
Cerenome Financial Results
Cerenome (formerly Plus Therapeutics) reported Q3 2026 financial results, highlighting its first quarter of CNSide diagnostic revenue totaling $0.7 million. The company expanded its payer coverage to approximately 190 million lives and completed enrollment in its Phase 2 glioblastoma trial. Additionally, the company rebranded from Plus Therapeutics to Cerenome during the quarter.
- Term
- Q3 2026
“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark. Furthermore, our payer universe continues to expand with now about 80% of U.S. private payers representing approximately 190 million covered lives. Most recently, with Aetna coverage, it gives physicians an in-network option for both tumor cell enumeration and molecular profiling. In parallel, our growing commercial team is focused on helping more cancer centers use our test in patient care. In therapeutics, we materially advanced our two key programs by completing enrollment in our Phase 2 trial in adults with recurrent glioblastoma, opening up higher dose cohorts in the repeat dosing of REYOBIQ™ in patients with leptomeningeal metastases and reporting interim data in that trial.”
Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer
Cerenome Executive Compensation
Cerenome, Inc. appointed Ronald A. Andrews as its new Chief Business Officer, effective November 9, 2026. Mr. Andrews, who already serves on the company's board, entered into an employment agreement providing for an annual base salary of $344,955, a 43% target bonus, and an option to purchase 92,858 shares of common stock.
- Counterparty
- Ronald A. Andrews
Cerenome Investor Presentation
Cerenome, Inc. (formerly Plus Therapeutics, Inc.) filed an updated corporate presentation as of September 30, 2026, for use in meetings with investors and analysts. The presentation covers the company's clinical trials, strategic collaborations, and the development of its CNSide platform for genomic testing.